
    
      Randomized, double-blind, placebo-controlled study. Inclusion Criteria: Obese women with body
      mass index (BMI)> 25 kg / mÂ², aged 18 years and LDL-C> 100 mg / dl For treatment with
      simvastatin 80 mg, the participant will receive two identical vials, each containing a
      simvastatin 40 mg. For treatment with the combination simvastatin 10 mg and ezetimibe 10 mg,
      the participant will receive two identical bottles, one bottle with simvastatin 10 mg, and
      another bottle with ezetimibe 10mg. In the control group, each participant will receive two
      identical bottles, each bottle containing inert tablets. Each group with 20 participants.

      Dependent Variable (Final Primary Outcome): Percentage change vasodilation of brachial artery
      flow-mediated, after treatment for eight weeks.

      Covariates: clinical, biochemical markers and ultrasound.
    
  